MARKET

VERU

VERU

Veru
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.20
-0.10
-0.89%
After Hours: 11.16 -0.04 -0.36% 19:49 07/01 EDT
OPEN
11.33
PREV CLOSE
11.30
HIGH
11.80
LOW
10.97
VOLUME
3.30M
TURNOVER
0
52 WEEK HIGH
17.50
52 WEEK LOW
4.340
MARKET CAP
896.83M
P/E (TTM)
-32.5203
1D
5D
1M
3M
1Y
5Y
Veru Inc. (VERU) Dips More Than Broader Markets: What You Should Know
Veru Inc. (VERU) closed the most recent trading day at $11.30, moving -1.31% from the previous trading session.
Zacks · 2d ago
Veru (NASDAQ:VERU) pulls back 15% this week, but still delivers shareholders incredible 61% CAGR over 5 years
It's been a soft week for Veru Inc. ( NASDAQ:VERU ) shares, which are down 15%. But that doesn't undermine the...
Simply Wall St. · 2d ago
Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MIAMI, June 24, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announc...
GlobeNewswire · 06/24 20:30
Veru Inc. (VERU) Gains As Market Dips: What You Should Know
Veru Inc. (VERU) closed at $13.54 in the latest trading session, marking a +1.12% move from the prior day.
Zacks · 06/22 22:15
Meridian Bioscience (VIVO) Moves 5.7% Higher: Will This Strength Last?
Meridian Bioscience (VIVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks · 06/20 08:49
Veru's Return On Capital Employed Insights
Veru (NASDAQ:VERU) brought in sales totaling $13.03 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 122.22%, resulting in a loss of $14.18 million.
Benzinga · 06/16 14:09
10 Most Shorted Stocks to Watch in June
In this article, we discuss the 10 most shorted stocks to watch in June. If you want to skip our analysis of these stocks, go directly to the 5 Most Shorted Stocks to Watch in June. Reports indicate that short-sellers are increasing their bets on the SPDR ...
Insider Monkey · 06/16 13:32
Hot Stocks: TGT warning; HOOD drops; ASO rises on earnings; VERU files for COVID drug
Reports of encroaching regulatory pressure sparked a decline in shares of Robinhood (NASDAQ:HOOD) during Tuesday's intraday trading. Worries that the U.S. security watchdog will curtail the firm's business model sent
Seekingalpha · 06/07 16:21
More
No Data
Learn about the latest financial forecast of VERU. Analyze the recent business situations of Veru through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VERU stock price target is 34.00 with a high estimate of 55.00 and a low estimate of 24.00.
High55.00
Average34.00
Low24.00
Current 11.20
EPS
Actual
Estimate
-0.14-0.11-0.07-0.04
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 121
Institutional Holdings: 23.05M
% Owned: 28.79%
Shares Outstanding: 80.07M
TypeInstitutionsShares
Increased
37
1.18M
New
10
316.98K
Decreased
36
1.55M
Sold Out
25
542.83K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Personal Products
+1.13%
Personal & Household Products & Services
+1.20%
Key Executives
Chairman/President/Chief Executive Officer/Director
Mitchell Steiner
Vice Chairman/Director
Harry Fisch
Chief Financial Officer/Chief Administrative Officer
Michele Greco
Chief Scientific Officer
K. Barnette
Independent Director
Mario Eisenberger
Independent Director
Grace Hyun
Independent Director
Lucy Lu
Independent Director
Michael Rankowitz
No Data
No Data
About VERU
Veru Inc. is an oncology biopharmaceutical company. The Company is focused on developing medicines for the management of breast and prostate cancers. The Company's FC2 segment consists of its commercial product, FC2. The Pharmaceuticals segment includes activities related to multiple drug products under clinical development and ENTADFI, a treatment for benign prostatic hyperplasia. It has a commercial Sexual Health Division, which includes two products, such as ENTADFI, a treatment for benign prostatic hyperplasia (BPH), and the FC2 Female Condom (Internal Condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Webull offers kinds of Veru Inc stock information, including NASDAQ:VERU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VERU stock methods without spending real money on the virtual paper trading platform.